Neurofibromatosis type I: Genetics and clinical manifestations

Seminars in Ophthalmology

Volumn 23, Issue 1, 2008, Pages 45-51

  Savar, Aaron ^a   Cestari, Dean M ^a  

^a MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

Author keywords

Genetics; Neurofibromatosis type I; Neurofibromin; NF1

Indexed keywords

NEUROFIBROMIN;

BONE DYSPLASIA; CAFE AU LAIT SPOT; CLINICAL FEATURE; DISEASE ASSOCIATION; GENETIC ANALYSIS; HUMAN; MOLECULAR GENETICS; NEUROFIBROMA; NEUROFIBROMATOSIS; OPTIC NERVE GLIOMA; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; REVIEW;

GENES, NEUROFIBROMATOSIS 1; HUMANS; NEUROFIBROMATOSIS 1; NEUROFIBROMIN 1;

EID: 38549160504     PISSN: 08820538     EISSN: 17445205     Source Type: Journal    
DOI: 10.1080/08820530701745223     Document Type: Review

References (48)

1. Akinci A, Acaroglu G, Guven A, Degerli A. Refractive errors in Neurofibromatosis type-1 and type-2. Br J Ophthalmol 2007 Jan 3; [Epub ahead of print].
2. Barker D, Wright E, Nguyen K, Cannon L, Fain P, Goldgar D, Bishop DT, Carey J, Baty B, Kivlin J, et al. Gene for von Recklinghausen neurofibromatosis is in the pericentromeric region of chromosome 17. Science 1987 May 29; 236(4805):1100-2.
3. Baser ME, Friedman JM, Evans DG. Increasing the specificity of diagnostic criteria for schwannomatosis. Neurology 2006 Mar 14; 66(5):730-2.
4. Beauchamp GR. Neurofibromatosis type 1 in children. Trans Am Ophthalmol Soc 1995; 93:445-72.
5. Bilgic B, Ates LE, Demiryont M, Ozger H, Dizdar Y. Malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1. Pathol Oncol Res 2003; 9(3):201-5.
6. Blazo MA, Lewis RA, Chintagumpala MM, Frazier M, McCluggage C, Plon SE. Outcomes of systematic screening for optic pathway tumors in children with Neurofibromatosis Type 1. Am J Med Genet A 2004 Jun 15; 127(3):224-9.
7. Colman SD, Williams CA, Wallace MR. Benign neurofibromas in type 1 neurofibromatosis (NF1) show somatic deletions of the NF1 gene. Nat Genet 1995 Sep; 11(1):90-2.
8. Creange A, Zeller J, Rostaing-Rigattieri S, Brugieres P, Degos JD, Revuz J, Wolkenstein P. Neurological complications of neurofibromatosis type 1 in adulthood. Brain 1999 Mar; 122 (Pt 3):473-81.
9. Dasgupta B, Dugan LL, Gutmann DH. The neurofibromatosis 1 gene product neurofibromin regulates pituitary adenylate cyclase-activating polypeptide-mediated signaling in astrocytes. J Neurosci 2003 Oct 1; 23(26):8949-54.
10. Daston MM, Ratner N. Neurofibromin, a predominantly neuronal GTPase activating protein in the adult, is ubiquitously expressed during development. Dev Dyn 1992 Nov; 195(3):216-26.
11. Daston MM, Scrable H, Nordlund M, Sturbaum AK, Nissen LM, Ratner N. The protein product of the neurofibromatosis type 1 gene is expressed at highest abundance in neurons, Schwann cells, and oligodendrocytes. Neuron 1992 Mar; 8(3):415-28.
12. De Schepper S, Boucneau J, Vander Haeghen Y, Messiaen L, Naeyaert JM, Lambert J. Cafe-au-lait spots in neurofibromatosis type 1 and in healthy control individuals: hyperpigmentation of a different kind? Arch Dermatol Res 2006 Apr; 297(10):439-49.
13. De Schepper S, Boucneau J, Lambert J, Messiaen L, Naeyaert JM. Pigment cell-related manifestations in neurofibromatosis type 1: an overview. Pigment Cell Res 2005 Feb; 18(1):13-24.
14. Destro M, D'Amico DJ, Gragoudas ES, Brockhurst RJ, Pinnolis MK, Albert DM, Topping TM, Puliafito CA. Retinal manifestations of neurofibromatosis. Diagnosis and management. Arch Ophthalmol 1991 May; 109(5):662-6.
15. Ducatman BS, Scheithauer BW, Piepgras DG, Reiman HM, Ilstrup DM. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer 1986 May 15; 57(10):2006-21.
16. Ferner RE, Huson SM, Thomas N, Moss C, Willshaw H, Evans DG, Upadhyaya M, Towers R, Gleeson M, Steiger C, Kirby A. Guidelines for the diagnosis and management of individuals with Neurofibromatosis 1 (NF1). J Med Genet 2006 Nov 14; [Epub ahead of print].
17. Friedman JM, Arbiser J, Epstein JA, Gutmann DH, Huot SJ, Lin AE, McManus B, Korf BR. Cardiovascular disease in neurofibromatosis 1: report of the NF1 Cardiovascular Task Force. Genet Med 2002 May-Jun; 4(3):105-11.
18. Friedrich RE, Heiland M, Kehler U, Schmelzle R. Reconstruction of sphenoid wing dysplasia with pulsating exophthalmos in a case of neurofibromatosis Type 1 supported by intraoperative navigation using a new skull reference system. Skull Base 2003 Nov; 13(4):211-17.
19. Griffiths S, Thompson P, Frayling I, Upadhyaya M. Molecular diagnosis of neurofibromatosis type 1: 2 years experience. Fam Cancer 2006 Aug 31; [Epub ahead of print].
20. Harrisingh MC, Lloyd AC. Ras/Raf/ERK signalling and NF1. Cell Cycle 2004 Oct; 3(10):1255-8.
21. Hyman SL, Shores A, North KN. The nature and frequency of cognitive deficits in children with neurofibromatosis type 1. Neurology 2005 Oct 11; 65(7):1037-44.
22. Jacquemin C, Bosley TM, Svedberg H. Orbit deformities in craniofacial neurofibromatosis type 1. Am J Neuroradiol 2003 Sep; 24(8):1678-82.
23. King A, Listernick R, Charrow J, Piersall L, Gutmann DH. Optic pathway gliomas in neurofibromatosis type 1: the effect of presenting symptoms on outcome. Am J Med Genet A 2003 Oct 1; 122(2):95-9.
24. Kaufman LM, Doroftei O. Optic glioma warranting treatment in children. Eye 2006 Oct; 20(10):1149-64.
25. Korf BR. Plexiform neurofibromas. Am J Med Genet 1999 Mar 26; 89(1):31-7.
26. Lazaro C, Ravella A, Gaona A, Volpini V, Estivill X. Neurofibromatosis type 1 due to germ-line mosaicism in a clinically normal father. N Engl J Med 1994 Nov 24; 331(21):1403-7.
27. Ledbetter DH, Rich DC, O'Connell P, Leppert M, Carey JC. Precise localization of NF1 to 17q11.2 by balanced translocation. Am J Hum Genet 1989 Jan; 44(1):20-4.
28. Lee V, Ragge NK, Collin JR. Orbitotemporal neurofibromatosis. Clinical features and surgical management. Ophthalmology 2004 Feb; 111(2):382-8.
29. Messiaen LM, Callens T, Mortier G, Beysen D, Vandenbroucke I, Van Roy N, et al. Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects. Hum Mutat 2000; 15:541-55.
30. National Institutes of Health Consensus Development Conference: Neurofibromatosis. Conference statement. Arch Neurol 1988 May; 45(5):575-8.
31. Origone P, Bonioli E, Panucci E, Costabel S, Ajmar F, Coviello DA. The Genoa experience of prenatal diagnosis in NF1. Prenat Diagn 2000 Sep; 20(9):719-24.
32. Otsuka F, Kawashima T, Imakado S, Usuki Y, Hon-mura S. Lisch nodules and skin manifestation in neurofibromatosis type 1. Arch Derm 2001; 137: 232-33.
33. Perren A, Wiesli P, Schmid S, Montani M, Schmitt A, Schmid C, Moch H, Komminoth P. Pancreatic endocrine tumors are a rare manifestation of the neurofibromatosis type 1 phenotype: molecular analysis of a malignant insulinoma in a NF-1 patient. Am J Surg Pathol 2006 Aug; 30(8):1047-51.
34. Quaranta L, Semeraro F, Turano R, Gandolfo E. Gonioscopic findings in patients with type 1 neurofibromatosis (Von Recklinghausen disease). J Glaucoma 2004 Apr; 13(2):90-5.
35. Rasmussen SA, Yang Q, Friedman JM. Mortality in neurofibromatosis 1: an analysis using U.S. death certificates. Am J Hum Genet 2001 May; 68(5):1110-8.
36. Rowinsky EK, Windle JJ, Von Hoff DD. Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development. J Clin Oncol 1999 Nov; 17(11):3631-52.
37. Ruggieri M, Polizzi A, Di Pietro M, Scuderi A, Gabriele A, Spalice A, Iannetti P. Ophthalmological manifestations in segmental neurofibromatosis type 1. Br J Ophthalmol 2004 Nov; 88(11):1429-33.
38. Shapira S, Barkan B, Fridman E, Kloog Y, Stein R. The tumor suppressor neurofibromin confers sensitivity to apoptosis by Ras-dependent and Ras-independent pathways. Cell Death Differ 2006 Nov 10; [Epub ahead of print].
39. Stevenson DA, Moyer-Mileur LJ, Murray M, Slater H, Sheng X, Carey JC, Dube B, Viskochil DH. Bone mineral density in children and adolescents with neurofibromatosis type 1. J Pediatr 2007 Jan; 150(1):83-8.
40. Sylvester CL, Drohan LA, Sergott RC. Optic-nerve gliomas, chiasmal gliomas and neurofibromatosis type 1. Curr Opin Ophthalmol 2006 Feb; 17(1):7-11.
41. Theos A, Korf BR. Pathophysiology of neurofibromatosis type 1. Ann Intern Med 2006 Jun 6; 144(11):842-9.
42. Thiagalingam S, Flaherty M, Billson F, North K. Neurofibromatosis type 1 and optic pathway gliomas: follow-up of 54 patients. Ophthalmology 2004 Mar; 111(3):568-77.
43. Tinschert S, Naumann I, Stegmann E, Buske A, Kaufmann D, Thiel G, Jenne DE. Segmental neurofibromatosis is caused by somatic mutation of the neurofibromatosis type 1 (NF1) gene. Eur J Hum Genet 2000 Jun; 8(6):455-9.
44. Trovo-Marqui AB, Tajara EH. Neurofibromin: a general outlook. Clin Genet 2006 Jul; 70(1):1-13.
45. Widemann BC, Salzer WL, Arceci RJ, Blaney SM, Fox E, End D, Gillespie A, Whitcomb P, Palumbo JS, Pitney A, Jayaprakash N, Zannikos P, Balis FM. Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas. J Clin Oncol 2006 Jan 20; 24(3):507-16.
46. Williamson TH, Garner A, Moore AT. Structure of Lisch nodules in neurofibromatosis type 1. Ophthalmic Paediatr Genet 1991 Mar; 12(1):11-7.
47. Wong WW, Hirose T, Scheithauer BW, Schild SE, Gunderson LL. Malignant peripheral nerve sheath tumor: analysis of treatment outcome. Int J Radiat Oncol Biol Phys 1998 Sep 1; 42(2):351-60.
48. Xu GF, O'Connell P, Viskochil D, Cawthon R, Robertson M, Culver M, Dunn D, Stevens J, Gesteland R, White R, et al. The neurofibromatosis type 1 gene encodes a protein related to GAP. Cell 1990 Aug 10; 62(3):599-608.